Kidney International

Papers
(The H4-Index of Kidney International is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases924
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease527
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases423
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease423
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe378
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference259
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy223
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease210
Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference207
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19205
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants202
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease196
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease187
Molecular mechanisms and therapeutic targets for diabetic kidney disease185
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule174
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine166
Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients149
Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification136
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy127
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial124
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference123
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence122
Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients120
NELL1 is a target antigen in malignancy-associated membranous nephropathy118
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains114
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant109
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients108
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice108
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglob108
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease105
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients103
Rationale and design of the Kidney Precision Medicine Project102
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis101
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics100
Occurrence of severe COVID-19 in vaccinated transplant patients100
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)98
ANCA glomerulonephritis after the Moderna COVID-19 vaccination97
A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19)96
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment94
Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis92
Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics91
Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy90
Allorecognition and the spectrum of kidney transplant rejection88
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis88
IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)85
A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination84
A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death83
Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine83
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients76
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action75
Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study73
Targeting inflammation to treat diabetic kidney disease: the road to 203072
De novo vasculitis after mRNA-1273 (Moderna) vaccination69
Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders68
Cystinuria: clinical practice recommendation68
Is COVID-19 vaccination unmasking glomerulonephritis?68
COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?68
The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults67
A practical guide to multiple imputation of missing data in nephrology66
Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy64
SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease64
Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference63
Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome63
0.15266799926758